Cadrenal Therapeutics (CVKD) Cash & Equivalents (2022 - 2026)

Cadrenal Therapeutics has reported Cash & Equivalents for 5 years, with the latest figure at $2.3 million in Q1 2026.

• Quarterly Cash & Equivalents fell 68.65% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (down 68.65% YoY) and the FY2025 annual result came in at $4.0 million, down 59.99% from the prior year.
• Cash & Equivalents retreated to $2.3 million in Q1 2026 per CVKD's latest filing, from $4.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $10.0 million in Q4 2024 and troughed at $32586.0 in Q4 2022.
• A 5-year average of $5.3 million and a median of $4.7 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2026: Cash & Equivalents soared 25685.61% in 2023, then plunged 68.65% in 2026.
• Over 5 years, Cash & Equivalents stood at $32586.0 in 2022, then jumped by 25685.61% to $8.4 million in 2023, then increased by 19.23% to $10.0 million in 2024, then slumped by 59.99% to $4.0 million in 2025, then slumped by 42.61% to $2.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $2.3 million, $4.0 million, and $3.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.